Table 5.
PROGRESS comorbidities
| Variable |
DrotAA n = 882 |
Non-DrotAA n = 11,610 |
Total n = 12,492 |
P value |
| Diabetes, n (%) | (n = 766) 164 (21.4) |
(n = 10,352) 2441 (23.6) |
(n = 11,118) 2605 (23.4) |
0.17 |
| Chronic lung disease, n (%) | (n = 870) 136 (15.6) |
(n = 11,447) 1924 (16.8) |
(n = 12,317) 2060 (16.7) |
0.37 |
| Active cancer, n (%) | (n = 844) 102 (12.1) |
(n = 11,101) 1787 (16.1) |
(n = 11,945) 1889 (15.8) |
0.002 |
| Congestive heart failure, n (%) | (n = 879) 97 (11.0) |
(n = 11,460) 1630 (14.2) |
(n = 12,339) 1727 (14.0) |
0.009 |
| Chronic renal insufficiency, n (%) | (n = 872) 54 (6.2) |
(n = 11,481) 1285 (11.2) |
(n = 12,353) 1339 (10.8) |
<0.001 |
| Chronic liver disease, n (%) | (n = 843) 48 (5.7) |
(n = 11,142) 727 (6.5) |
(n = 11,985) 775 (6.5) |
0.34 |
| Other, n (%) | (n = 768) 197 (25.7) |
(n = 10,369) 2473 (23.9) |
(n = 11,125) 2670 (24.0) |
0.90 |
DrotAA = drotrecogin alfa (activated); PROGRESS = Promoting Global Research Excellence in Severe Sepsis.